Achim Rittmeyer
- Oncology top 0.2%
- Pulmonary and Respiratory Medicine top 0.5%
- Immunology top 2%
- Cancer Research top 2%
- Molecular Biology
- Co-authors
- Marcin KowanetzAlan SandlerMarcus BallingerKeunchil ParkJulien MazièresLouis FehrenbacherDaniel WaterkampJohan Vansteenkiste
- Topics
- Lung Cancer Treatments and Mutations (58 papers)Cancer Immunotherapy and Biomarkers (52 papers)Lung Cancer Research Studies (22 papers)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Achim Rittmeyer
84 papers receiving 5.6k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 4.9k
- Pulmonary and Respiratory Medicine 3.5k
- Immunology 1.1k
- Cancer Research 687
- Molecular Biology 593
Countries citing papers authored by Achim Rittmeyer
This map shows the geographic impact of Achim Rittmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Achim Rittmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Achim Rittmeyer more than expected).
Fields of papers citing papers by Achim Rittmeyer
This network shows the impact of papers produced by Achim Rittmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Achim Rittmeyer. The network helps show where Achim Rittmeyer may publish in the future.
Co-authorship network of co-authors of Achim Rittmeyer
This figure shows the co-authorship network connecting the top 25 collaborators of Achim Rittmeyer. A scholar is included among the top collaborators of Achim Rittmeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Achim Rittmeyer. Achim Rittmeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 6 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialbreakdown → | 126 |
| 6 | 12 | |
| 7 | 14 | |
| 8 | 10 | |
| 9 | 201 | |
| 10 | 21 | |
| 11 | 0 | |
| 12 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialbreakdown → | 1137 |
| 13 | 53 | |
| 14 | 132 | |
| 15 | 13 | |
| 16 | 17 | |
| 17 | 12 | |
| 18 | 56 | |
| 19 | 2 | |
| 20 | 23 |
About Achim Rittmeyer
Achim Rittmeyer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 91 papers that have together received 5.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (58 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (22 papers). The work is most often cited by research in Oncology (4.9k citations), Pulmonary and Respiratory Medicine (3.5k citations) and Immunology (1.1k citations). Achim Rittmeyer has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Marcin Kowanetz, Alan Sandler, Marcus Ballinger, Keunchil Park, Julien Mazières, Louis Fehrenbacher, Daniel Waterkamp, Johan Vansteenkiste, Alexander I. Spira and Pei He. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.